HOME >> MEDICINE >> NEWS
Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA

ational achievement, as approximately 17 percent of the adults surveyed with ADHD did not graduate high school, while only seven percent of those without ADHD did not graduate from high school. Untreated ADHD may also increase the risk for other problems, such as anti-social behavior, poor self-esteem and drug abuse, all of which can further impair social and family relationships, Grcevich explained.

After these adolescent patients completed a four-week placebo-controlled trial with ADDERALL XR, they entered into a six-month open-label extension study. Analysis of the four-week data revealed that ADDERALL XR, compared with placebo, produces statistically and clinically significant improvements in core ADHD symptoms in adolescents. Both ADDERALL XR-nave adolescents as well as those who previously received ADDERALL XR showed continued symptomatic improvement during long-term ADDERALL XR treatment. ADDERALL XR was also found to be a well-tolerated once-daily treatment for the management of ADHD in adolescents.

Investigators measured adolescent patients' symptoms using two efficacy measures. The primary measure was the clinician-administered ADHD Rating Scale-IV (ADHD-RS) measured at baseline, weekly (short-term) and monthly (long-term) intervals. The ADHD-RS assesses the 18 individual items related to ADHD that are listed within in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TRTM). Nine of these items assess inattentive symptoms and the other nine items assess hyperactive and impulsive symptoms. Sample rating categories include "avoids tasks that require sustained mental effort" and "talks excessively."

The initial 4-week study was divided into primary and secondary cohorts. The primary cohort was comprised of adolescents weighing over or equal to 165 lb who met DSM-IV- TRTM ADHD criteria for ADHD. Subjects received randomized doses of ADDERALL XR or placebo once daily for four weeks
'"/>

Contact: Marion E. Glick
917-301-4206
Porter Novelli
20-Oct-2004


Page: 1 2 3

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
6. Long-term use of antibiotics possibly linked with increased risk of breast cancer
7. Long-term follow-up of mortality in patients with community-acquired pneumonia
8. Long-term outcome of epilepsy surgery is favorable for many
9. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
10. Long-term avoidance of milk in children results in poor bone health
11. Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

Post Your Comments:
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... (PROVIDENCE, R.I.) Casual, no-strings sexual encounters are ... students more likely than others to "hook up"? ... Hospital,s Centers for Behavioral and Preventive Medicine, published ... , suggests there are certain factors and behaviors ... women. , "Given the potential for negative ...
(Date:6/19/2013)... body,s system for repairing damage to the genetic material ... it may seem, those compounds are sparking optimism as ... a mutation in BRCA, a gene that made headlines ... The compounds, termed PARP inhibitors, are the topic of ... Chemical & Engineering News . C&EN is the weekly ...
(Date:6/19/2013)... at Louisiana State University have developed a method for ... relies on understanding the genetic interaction between single nucleotide ... prostate cancer,s aggressiveness to avoid unnecessary radical treatment. ... PLOS ONE in April. , According to ... all cancers and 9 percent of cancer deaths. It ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Alternatives, a ... some patients to quit using drugs while allowing them ... Jaffe, the founders of Alternatives, believe that abstinence-only approaches ... they enter treatment and that this approach hurts instead ... people in the United States need treatment for addiction ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
(Date:6/19/2013)... Calif. , June 19, 2013   ... today announces a licensing agreement granting Suzhou Ribo ... and manufacture siRNA therapeutics in China ...  Ribo will formulate proprietary siRNA molecules in combination ... designed to address human diseases with high unmet ...
(Date:6/19/2013)... 19. Juni 2013 Specialty ... der Entwicklung von SCS microRESIST™, einer ... der Beschichtung mit Parylene gelungen ist. ... biokompatiblem Parylene mit antimikrobiellen Eigenschaften und ... Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: